Kazia Therapeutics Shares Rise Following Guggenheim's 'Buy' Rating
Kazia Therapeutics (KZIA) saw positive trading momentum on Wednesday following the initiation of coverage by Guggenheim. The brokerage assigned a 'Buy' rating to the company, specifically citing optimism surrounding its lead drug candidate, paxalisib. This analyst upgrade follows a similar bullish sentiment from Leerink Partners earlier in the week. The consecutive positive ratings from major brokerages suggest growing institutional confidence in Kazia's clinical pipeline and the potential market trajectory of paxalisib.
Tickers: $KZIA
Topics: Biotechnology Equity Research Stock Rating